Depending on a variety of factors, there are various options for the treatment of genitourinary cancers (included bladder, kidney, and prostate cancers) including immunotherapy. This guide, published by Patient Resource Publishing in partnership with the Society for Immunotherapy of Cancer (SITC), provides information on current immunotherapy options for bladder, kidney, and prostate cancers, and explains the role of the immune system in cancer treatment and what to expect while undergoing treatment. Published 2020.#ClinicalTrials#BladderCancer#GenitourinaryCancers#ProstateCancer#PatientResourceGuides#AdverseEvents#SideEffects#Patient#PatientAdvocate#ImmuneCheckpointInhibitors#Cytokines#Vaccines#RenalCellCarcinoma#Pembrolizumab#Tcells#Bcells#Atezolizumab#Avelumab#Durvalumab#Nivolumab#Naturalkillercells
This library resource entry requires a SITC CONNECT account. Click the Sign In button at the top of this page, otherwise click here to create a FREE SITC CONNECT.
With a free SITC CONNET account, you can begin accessing hundreds of cancer immunotherapy resources in the SITC CONNECT Archive and Resource Libraries. Once your account is created, return to this page, refresh, and a download link should appear.
The SITC connectED education portal is supported by independent educational grants from AstraZeneca Pharmaceuticals LP and Merck & Co., Inc.
Join
Renew
Member Directory
My Profile
Volunteer
Support SITC
Job Board
Contact Us